Why the study?
Biodegradable polymer DESs were postulated to be superior to durable polymer DESs, but no study had demonstrated superiority of one polymer type over the other.
Do biodegradable polymer drug-eluting stents improve the device-oriented composite endpoint compared to durable polymer drug-eluting stents in all-comer patients undergoing PCI?
Do biodegradable polymer drug-eluting stents improve the device-oriented composite endpoint compared to durable polymer drug-eluting stents in all-comer patients undergoing PCI?
In an all-comer PCI population, biodegradable polymer DES and durable polymer DES showed similar 2-year composite clinical outcomes, though durable polymer DES was associated with a lower risk of acute stent thrombosis.
Answers are grounded in this paper and cite their sources.
Comparable DOCE with BP-DES and DP-DES in all-comer PCI; leaves open acute thrombosis differences and requires randomized confirmation.
BACKGROUND: Drug-eluting stents (DESs) have become the gold standard of coronary angioplasty since their inception in 2002. Biodegradable polymer DESs (BP-DESs) have been postulated to be superior to durable polymer DESs (DP-DESs) due to their more biocompatible polymer. To date, no study has shown the superiority of one type of polymer compared with the other. We aimed to compare outcomes between a broad range of second-generation DP-DES and BP-DES in an all-comer population. METHODS: We analysed data from 2824 patients who underwent percutaneous coronary intervention (PCI) with BP-DES or DP-DES in the Cardio-FR database. Of these, 2079 (1286 DP-DES and 793 BP-DES) met the inclusion and exclusion criteria and completed a 2-year follow-up: The primary outcome was the device-oriented composite endpoint (DOCE) of cardiac death, non-fatal target vessel myocardial infarction and target lesion revascularisation. RESULTS: Mean age was 67 years, with 75% male. Despite the DP-DES group exhibiting significantly higher rates of risk factors, such as arterial hypertension (63.1% vs 57.5%, p=0.010), a greater average number of stents implanted per patient (1.72±0.92 vs 1.63±0.84, p=0.040), more acute coronary syndrome (ACS) (55.1% vs 50.2%, p=0.031) and a higher rate of post-dilatation (42.2% vs 35.2%, p<0.001), the rate of acute stent thrombosis (ST) was significantly lower than in the BP-DES group (HR 0.240, 95% CI 0.075 to 0.766; p=0.016). This difference remained significant even after adjusting for covariates using a Cox proportional hazards model and performing a win ratio analysis (4.09, 95% CI 1.28 to 13.09; p=0.018). Despite this increased rate of acute ST, there was no difference in DOCE (12.1% vs 14.5%, OR 1.218, 95% CI 0.926 to 1.600; p=0.158) between the two groups up to 2 years. CONCLUSION: Clinical follow-up up to 2 years shows similar outcomes between BP-DES and DP-DES. The rate of acute ST is higher in patients with BP-DES.
No takes yet. Share an insight, caveat, or question.
Witzig et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: